Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 29 (oversold) · MACD below its signal · 3% above its 52-week low
None of the 29 investors followed here reported a position in ACTU in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ACTU trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Schmitt Daniel M.Chief Executive Officer | — | 272.1K | — |
| Feb 12, 2026 | Schmitt Daniel M.Chief Executive Officer | — | 272.1K | — |
| Jan 4, 2026 | Thomson Todd S.Director and Beneficial Owner of more than 10% of a Class of Security | Sale at price 5.80 per share. | 280K | $1.62M |
| Jun 26, 2025 | Bios Equity Cof, LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 7.00 per share. | 71.4K | $500.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -23.0 | -20.6 | -26.7 | 7.3 | -31.3 | -24.3 | -27.5 | 36.9 | -48.7 | -45.8 | −93.1% | ||
| 2025 | 13.4 | -19.8 | -6.5 | 35.9 | 29.3 | -48.7 | 18.7 | 16.4 | -20.7 | -0.4 | 14.6 | -19.8 | −23.1% |
| 2024 | -7.5 | 9.1 | 0.0 | -2.1 | −1.1% |
Buy / hold / sell counts
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.